Cargando…
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
PURPOSE OF REVIEW: RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella. RECENT FINDINGS: RNA therapeutics are designed to regula...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975710/ https://www.ncbi.nlm.nih.gov/pubmed/35364795 http://dx.doi.org/10.1007/s11883-022-01007-9 |
_version_ | 1784680424569569280 |
---|---|
author | Bejar, Nada Tat, Trinh T. Kiss, Daniel L. |
author_facet | Bejar, Nada Tat, Trinh T. Kiss, Daniel L. |
author_sort | Bejar, Nada |
collection | PubMed |
description | PURPOSE OF REVIEW: RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella. RECENT FINDINGS: RNA therapeutics are designed to regulate gene expression in a transient manner. For example, depending upon the strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. RNA therapies include antisense nucleotides, microRNAs and small interfering RNAs, RNA aptamers, and messenger RNAs. Further, we discuss the mechanism(s) by which different RNA therapies either reduce or increase the expression of their targets. SUMMARY: We review the RNA therapeutics approved (and those in trials) to treat cardiovascular indications. RNA-based therapeutics are a new, rapidly growing class of drugs that will offer new alternatives for an increasing array of cardiovascular conditions. |
format | Online Article Text |
id | pubmed-8975710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-89757102022-04-04 RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases Bejar, Nada Tat, Trinh T. Kiss, Daniel L. Curr Atheroscler Rep Vascular Biology (H. Pownall, Section Editor) PURPOSE OF REVIEW: RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella. RECENT FINDINGS: RNA therapeutics are designed to regulate gene expression in a transient manner. For example, depending upon the strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. RNA therapies include antisense nucleotides, microRNAs and small interfering RNAs, RNA aptamers, and messenger RNAs. Further, we discuss the mechanism(s) by which different RNA therapies either reduce or increase the expression of their targets. SUMMARY: We review the RNA therapeutics approved (and those in trials) to treat cardiovascular indications. RNA-based therapeutics are a new, rapidly growing class of drugs that will offer new alternatives for an increasing array of cardiovascular conditions. Springer US 2022-04-02 2022 /pmc/articles/PMC8975710/ /pubmed/35364795 http://dx.doi.org/10.1007/s11883-022-01007-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Vascular Biology (H. Pownall, Section Editor) Bejar, Nada Tat, Trinh T. Kiss, Daniel L. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title | RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title_full | RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title_fullStr | RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title_full_unstemmed | RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title_short | RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases |
title_sort | rna therapeutics: the next generation of drugs for cardiovascular diseases |
topic | Vascular Biology (H. Pownall, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975710/ https://www.ncbi.nlm.nih.gov/pubmed/35364795 http://dx.doi.org/10.1007/s11883-022-01007-9 |
work_keys_str_mv | AT bejarnada rnatherapeuticsthenextgenerationofdrugsforcardiovasculardiseases AT tattrinht rnatherapeuticsthenextgenerationofdrugsforcardiovasculardiseases AT kissdaniell rnatherapeuticsthenextgenerationofdrugsforcardiovasculardiseases |